Neuropace INC Form 4 insider transactions

NeuroPace Inc. reports a transaction involving Chief Medical Officer Martha Morrell's beneficial ownership of common stock.

Director R. Scott Huennekens acquired 2,890 shares of common stock and options for 5,368 shares in NeuroPace, Inc.

Director Frank M. Fischer acquired 2,890 shares of common stock and 5,368 stock options as part of a compensation grant.

Director Uri Geiger acquired 2,890 shares of common stock and 5,368 stock options in NeuroPace, Inc. as part of annual compensation.

Director Rakhi Kumar acquired 2,890 shares of common stock and 5,368 stock options in NeuroPace, Inc. as part of a compensation grant.

Director Renee Ryan acquired 2,890 shares of common stock and 5,368 stock options as part of a standard equity compensation grant.

Director Lisa Andrade acquired 2,890 shares of common stock and 5,368 stock options as part of a standard equity compensation grant.

NeuroPace Inc. CEO Joel Becker reported a transaction involving the withholding of shares to cover tax obligations upon the vesting of restricted stock units.

CEO Joel Becker reported the withholding of 1,126 shares of NeuroPace common stock to satisfy tax obligations related to RSU vesting.

Chief Medical Officer Martha Morrell disposed of 358 shares of NeuroPace common stock to satisfy tax withholding obligations.

NeuroPace Inc. reports Chief Financial Officer Patrick F. Williams acquired restricted stock units and stock options on May 15, 2026, as detailed in a Form 4 filing.

NeuroPace Inc. Chief Medical Officer Martha Morrell reports transactions involving restricted stock units and stock options.

NeuroPace CEO Joel Becker acquired 45,880 shares and was granted options for 122,190 shares on May 15, 2026.

NeuroPace Inc.'s Chief Medical Officer, Martha Morrell, disposed of 1,341 shares of common stock to cover tax withholding obligations related to a restricted stock unit award.

NeuroPace Inc. Director Uri Geiger acquired 913 shares of common stock at $13 per share as part of his non-employee director compensation.

NeuroPace Inc. Director Joseph Lacob acquired 865 shares of common stock at $13 per share as part of his non-employee director compensation.

NeuroPace Inc. Director Rakhi Kumar acquired 1,153 shares of common stock at $13 per share as part of her non-employee director compensation.

NeuroPace Inc. Director Frank M. Fischer acquired 1,826 shares of common stock as part of his non-employee director compensation.

NeuroPace's Chief Medical Officer, Martha Morrell, filed a Form 4 detailing planned sales of 25,000 common shares and future tax-related withholding of 1,340 shares.

NeuroPace Inc. CEO Joel Becker reported a tax-related disposition of 5,023 common shares at $13.83 per share on March 3, 2026, following a restricted stock unit vesting.

NeuroPace Inc. CEO Joel Becker reported a tax-related disposition of 1,126 common shares following a restricted stock unit vesting.

NeuroPace Inc.'s Chief Medical Officer, Martha Morrell, disposed of 358 shares of common stock to cover tax withholding obligations related to a restricted stock unit award.

NeuroPace Inc.'s Chief Medical Officer, Martha Morrell, had 3,412 shares withheld to cover tax obligations upon the vesting of a restricted stock unit award on February 20, 2026.

NeuroPace Inc. Director Joseph Lacob acquired 678 shares of common stock at $16.59 per share as part of his non-employee director compensation policy.

NeuroPace Director Rakhi Kumar acquired 904 shares of common stock at $16.59 per share as part of her compensation.

NeuroPace Inc. Director Uri Geiger acquired 715 shares of common stock at $16.59 per share as part of his compensation.

NeuroPace Director Frank M. Fischer acquired 1,431 shares of common stock at $16.59 per share as part of his non-employee director compensation policy.

NeuroPace Inc.'s Chief Medical Officer, Martha Morrell, reported the disposition of 1,338 common shares to cover tax obligations related to a restricted stock unit vesting.

NeuroPace Inc. CEO Joel Becker reported a disposition of 1,126 common shares to cover tax obligations related to a restricted stock unit award vesting.

NeuroPace Inc.'s Chief Medical Officer, Martha Morrell, reported a routine disposition of 357 shares of common stock to cover tax obligations related to a restricted stock unit award vesting.